Immune checkpoint inhibitor-induced cutaneous toxicities: a review of histopathologic and clinical features

• Published in: Human pathology Vol. 140; pp. 144 - 172
• Main Authors: Martel, Julianna, Hanania, Hannah L., Patel, Anisha B.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2023
• Subjects: Checkpoint inhibitor; CTLA-4; Cutaneous; Drug rash; Immunotherapy; PD-1; PD-L1; Checkpoint inhibitor; Drug rash; Immunotherapy; PD-L1; CTLA-4; PD-1; Cutaneous

Immune checkpoint inhibitors (ICIs) represent an emerging treatment option for a variety of cancer types. Through inhibition of programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1), and/or cytotoxic lymphocyte-associated antigen-4 (CTLA-4), ICIs activate the host's imm...